@curator

2 years ago

Article

After price deal, Takeda's lung cancer drug Exkivity wins UK green light

Rating: 0.0

Likes: 1

Library: 1

After price deal, Takeda's lung cancer drug Exkivity wins UK green light

In their running battle to treat a rare form of non-small cell lung cancer, Johnson & Johnson and Takeda have been vying for regulatory approvals in the United States and U.K. | England has conditionally approved Takeda's Exkivity for non-small cell lung cancer patients whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations after chemotherapy and disease progression. In the rare form of the disease, Takeda is battling Johnson & Johnson's Rybrevant.

Rate This Post

Rate The Educational Value

Rate The Ease of Understanding and Presentation

Interesting or Boring? Rate the Entertainment Value

After price deal, Takeda's lung cancer drug Exkivity wins UK green light

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge
for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge
for Humanity's Progress

After price deal, Takeda's lung cancer drug Exkivity wins UK green light

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress